Lonza Group Ltd. has announced changes to its executive committee (EC), reportedly to ensure the continuity and focused delivery of its pharmaceuticals and biotechnology division growth strategy. As of July 1, 2014, Marc Funk will take on the full leadership role for the Pharma&Biotech segment. Also, Stephan Kutzer announced he will leave Lonza but ensure his duties are handed over by that date. For a period of time, he will continue transitional activities as required.
“Marc has been the group’s chief legal officer and board secretary since 2009, and a member of the EC since 2012,” said Richard Ridinger, CEO of Lonza, in a press statement. “He has already successfully managed operational and commercial projects in the Pharma&Biotech network, and has been responsible for global quality in Pharma&Biotech for more than a year. Also, he has broad experience in this field as he was formerly co-founder of a biotech research company; [he additionally] has had a strong commercial focus in other parts of his career. I am confident he’ll be able to steer that segment through this critical growth phase and into the future.”
During the transition period, Funk will continue as the Group’s chief legal officer and board secretary until his successor for this role is announced.
